Physician
Central Valley Pain Management and Wellness Clinic
Central Valley Pain Management and Wellness Clinic was paid $208K by Medicaid between Jan 2018 and Nov 2024, across 10 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 67% of everything it billed.
33Billing provider infoCENTRAL VALLEY PAIN MANAGEMENT AND WELLNESS CLINIC
MODESTO, CA 95355
MODESTO, CA 95355
33aNPI1871657403assigned 12/20/2006
33bProvider typePain Medicine Physician
28Total paid$208K
24GClaims9,949
24DCodes billed10
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Pain Medicine Physician providers in California
Rank by total paid#12 of 35
Median peer was paid$96K
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 637 | $13K | |
| 2019 | 1,124 | $30K | |
| 2020 | 2,652 | $33K | |
| 2021 | 865 | $27K | |
| 2022 | 767 | $13K | |
| 2023 | 1,864 | $39K | |
| 2024incomplete | 2,040 | $53K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 67% | 4,398 | 4,276 | $139K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 2,301 | 2,249 | $49K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 6.7% | 656 | 652 | $14K |
| 80305 | 1.5% | 769 | 762 | $3K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.5% | 330 | 321 | $3K |
| 99000 | <1% | 31 | 31 | $7.26 | |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 484 | 479 | $0.00 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 484 | 479 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 483 | 478 | $0.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 13 | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRHOADES, PATRICK (PRESIDENT)